BG108569A - Инхалационни състави, съдържащи трициклени 5,6-дихидро-9н-пиразоло[3,4-с]-1,2,4-триазоло[4,3-алфа]пиридини - Google Patents
Инхалационни състави, съдържащи трициклени 5,6-дихидро-9н-пиразоло[3,4-с]-1,2,4-триазоло[4,3-алфа]пиридини Download PDFInfo
- Publication number
- BG108569A BG108569A BG108569A BG10856904A BG108569A BG 108569 A BG108569 A BG 108569A BG 108569 A BG108569 A BG 108569A BG 10856904 A BG10856904 A BG 10856904A BG 108569 A BG108569 A BG 108569A
- Authority
- BG
- Bulgaria
- Prior art keywords
- dihydro
- alkyl
- pyrazolo
- ethyl
- pyridine
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 150000003222 pyridines Chemical class 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 37
- 239000002245 particle Substances 0.000 claims abstract description 30
- 239000007787 solid Substances 0.000 claims abstract description 14
- 208000023504 respiratory system disease Diseases 0.000 claims abstract description 9
- 201000010099 disease Diseases 0.000 claims abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
- 210000004072 lung Anatomy 0.000 claims abstract description 7
- 238000011282 treatment Methods 0.000 claims abstract description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 40
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 239000001257 hydrogen Substances 0.000 claims description 20
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 19
- 239000000843 powder Substances 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 12
- 239000008101 lactose Substances 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 229940112141 dry powder inhaler Drugs 0.000 claims description 11
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- 239000000725 suspension Substances 0.000 claims description 9
- -1 1-methylcyclohex-1-yl Chemical group 0.000 claims description 8
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 239000004005 microsphere Substances 0.000 claims description 8
- 208000006673 asthma Diseases 0.000 claims description 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 6
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 6
- 229910005965 SO 2 Inorganic materials 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims description 5
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 claims description 5
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 claims description 4
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 125000004399 C1-C4 alkenyl group Chemical group 0.000 claims description 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000006199 nebulizer Substances 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 3
- 125000006833 (C1-C5) alkylene group Chemical group 0.000 claims description 2
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- SNTWKPAKVQFCCF-UHFFFAOYSA-N 2,3-dihydro-1h-triazole Chemical compound N1NC=CN1 SNTWKPAKVQFCCF-UHFFFAOYSA-N 0.000 claims description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 claims description 2
- CEMQXLVYSIOKKQ-UHFFFAOYSA-N chembl218653 Chemical compound C1CN(C(=NN=2)C=3C(=CC=CC=3)Cl)C=2C2=C1C(CC)=NN2C1CCCC1 CEMQXLVYSIOKKQ-UHFFFAOYSA-N 0.000 claims description 2
- WXCVZXZNCSCEFF-UHFFFAOYSA-N chembl219192 Chemical compound C1CN(C(=NN=2)C=3C(=CC=CC=3)C)C=2C2=C1C(CC)=NN2C1CCCC1 WXCVZXZNCSCEFF-UHFFFAOYSA-N 0.000 claims description 2
- AJOWVHDRHWCPEK-UHFFFAOYSA-N chembl376440 Chemical compound C1CN2C(C3=CSC=C3)=NN=C2C2=C1C(CC)=NN2C1CCCC1 AJOWVHDRHWCPEK-UHFFFAOYSA-N 0.000 claims description 2
- IWPHDQBTRZYUAV-UHFFFAOYSA-N chembl387479 Chemical compound C1CN(C(=NN=2)C=3N=CC=CC=3)C=2C2=C1C(CC)=NN2C1CCCC1 IWPHDQBTRZYUAV-UHFFFAOYSA-N 0.000 claims description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000006304 2-iodophenyl group Chemical group [H]C1=C([H])C(I)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- VFNVUSQFRKXKQI-UHFFFAOYSA-N chembl218221 Chemical compound C1CN2C(CCC)=NN=C2C2=C1C(CC)=NN2C1CCCC1 VFNVUSQFRKXKQI-UHFFFAOYSA-N 0.000 claims 1
- DICDEJDXIQKUPO-UHFFFAOYSA-N chembl219223 Chemical compound C1CN(C(=NN=2)C=3C(=CC=CC=3)C(F)(F)F)C=2C2=C1C(CC)=NN2C1CCCC1 DICDEJDXIQKUPO-UHFFFAOYSA-N 0.000 claims 1
- 150000004682 monohydrates Chemical class 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 206010011224 Cough Diseases 0.000 abstract description 15
- 238000009472 formulation Methods 0.000 abstract description 5
- BAIYDCLETZLHLQ-UHFFFAOYSA-N C1CN2C=NN=C2C2=C1C=NN2 Chemical class C1CN2C=NN=C2C2=C1C=NN2 BAIYDCLETZLHLQ-UHFFFAOYSA-N 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 239000002775 capsule Substances 0.000 description 11
- 229960001375 lactose Drugs 0.000 description 11
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 8
- 229960001021 lactose monohydrate Drugs 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 4
- DHCOPPHTVOXDKU-UHFFFAOYSA-N Tofimilast Chemical compound C1CN2C(C=3SC=CC=3)=NN=C2C2=C1C(CC)=NN2C1CCCC1 DHCOPPHTVOXDKU-UHFFFAOYSA-N 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PHIVEUQACADDGU-UHFFFAOYSA-N chembl218103 Chemical compound C1CN(C(=NN=2)C(C)(C)C)C=2C2=C1C(CC)=NN2C1CCCC1 PHIVEUQACADDGU-UHFFFAOYSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 229940071648 metered dose inhaler Drugs 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- CZSOESDMMFWTJY-UHFFFAOYSA-N 12-cyclopentyl-10-ethyl-5-(2-iodophenyl)-3,4,6,11,12-pentazatricyclo[7.3.0.02,6]dodeca-1(9),2,4,10-tetraene Chemical compound C1CN(C(=NN=2)C=3C(=CC=CC=3)I)C=2C2=C1C(CC)=NN2C1CCCC1 CZSOESDMMFWTJY-UHFFFAOYSA-N 0.000 description 1
- FABWMAMCDJJROT-UHFFFAOYSA-N 3,4,6,11,12-pentazatricyclo[7.3.0.02,6]dodeca-1(9),2,4,7,10-pentaene Chemical compound C1=CN2C=NN=C2C2=C1C=NN2 FABWMAMCDJJROT-UHFFFAOYSA-N 0.000 description 1
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 description 1
- NVOYVOBDTVTBDX-AGUVMIOSSA-N 8g15t83e6i Chemical compound C1([C@@H](CO)C(=O)OC2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CC)=CC=CC=C1 NVOYVOBDTVTBDX-AGUVMIOSSA-N 0.000 description 1
- ZNUJAZSDJXSBIG-YVIFWTNJSA-N 9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(2,2-diphenylethylamino)-n-(2-piperidin-1-ylethyl)purine-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC(C(=O)NCCN3CCCCC3)=NC(NCC(C=3C=CC=CC=3)C=3C=CC=CC=3)=C2N=C1 ZNUJAZSDJXSBIG-YVIFWTNJSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102100039705 Beta-2 adrenergic receptor Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 101150049660 DRD2 gene Proteins 0.000 description 1
- 229940098778 Dopamine receptor agonist Drugs 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012512 bulk drug substance Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- RCTFEKPBUAMARW-UHFFFAOYSA-N chembl218053 Chemical compound C1CN(C(=NN=2)C=3C(=CC=CC=3)OC)C=2C2=C1C(CC)=NN2C1CCCC1 RCTFEKPBUAMARW-UHFFFAOYSA-N 0.000 description 1
- KTGGFYABBZGGFN-UHFFFAOYSA-N chembl218696 Chemical compound C1CN2C(C=3OC=CC=3)=NN=C2C2=C1C(CC)=NN2C1CCCC1 KTGGFYABBZGGFN-UHFFFAOYSA-N 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- HVCNNTAUBZIYCG-UHFFFAOYSA-N ethyl 2-[4-[(6-chloro-1,3-benzothiazol-2-yl)oxy]phenoxy]propanoate Chemical compound C1=CC(OC(C)C(=O)OCC)=CC=C1OC1=NC2=CC=C(Cl)C=C2S1 HVCNNTAUBZIYCG-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
- 229960001888 ipratropium Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 1
- 229940110309 tiotropium Drugs 0.000 description 1
- ZOTHAEBAWXWVID-HXEFRTELSA-N uk-432,097 Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC(C(=O)NCCNC(=O)NC3CCN(CC3)C=3N=CC=CC=3)=NC(NCC(C=3C=CC=CC=3)C=3C=CC=CC=3)=C2N=C1 ZOTHAEBAWXWVID-HXEFRTELSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M13/00—Insufflators for therapeutic or disinfectant purposes, i.e. devices for blowing a gas, powder or vapour into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0122031.8A GB0122031D0 (en) | 2001-09-12 | 2001-09-12 | Use of pde4 inhibitors in a dry powder inhaler |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG108569A true BG108569A (bg) | 2005-02-28 |
Family
ID=9921954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG108569A BG108569A (bg) | 2001-09-12 | 2004-02-09 | Инхалационни състави, съдържащи трициклени 5,6-дихидро-9н-пиразоло[3,4-с]-1,2,4-триазоло[4,3-алфа]пиридини |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US20030064034A1 (xx) |
| EP (1) | EP1427414A1 (xx) |
| JP (1) | JP2005505560A (xx) |
| KR (1) | KR20040036940A (xx) |
| CN (1) | CN1553801A (xx) |
| AP (2) | AP2002002623A0 (xx) |
| AR (2) | AR036473A1 (xx) |
| BG (1) | BG108569A (xx) |
| BR (1) | BR0212449A (xx) |
| CA (1) | CA2457717A1 (xx) |
| CZ (1) | CZ2004310A3 (xx) |
| EA (1) | EA006742B1 (xx) |
| EC (1) | ECSP045018A (xx) |
| EE (1) | EE200400078A (xx) |
| GB (1) | GB0122031D0 (xx) |
| HN (2) | HN2002000253A (xx) |
| HR (1) | HRP20040162A2 (xx) |
| HU (1) | HUP0401890A3 (xx) |
| IL (1) | IL160380A0 (xx) |
| IS (1) | IS7151A (xx) |
| MA (1) | MA27062A1 (xx) |
| MX (1) | MXPA04002354A (xx) |
| NO (1) | NO20041011L (xx) |
| NZ (1) | NZ530929A (xx) |
| OA (1) | OA12660A (xx) |
| PA (2) | PA8554701A1 (xx) |
| PE (2) | PE20030443A1 (xx) |
| PL (1) | PL368736A1 (xx) |
| SK (1) | SK1272004A3 (xx) |
| SV (2) | SV2004001227A (xx) |
| TN (1) | TNSN04040A1 (xx) |
| TW (1) | TW200602054A (xx) |
| WO (2) | WO2003022275A1 (xx) |
| ZA (1) | ZA200401002B (xx) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7931022B2 (en) | 2001-10-19 | 2011-04-26 | Respirks, Inc. | Method and apparatus for dispensing inhalator medicament |
| AU2003302274A1 (en) * | 2002-12-31 | 2004-07-29 | Novartis Ag | Aerosolizable pharmaceutical formulation for fungal infection therapy |
| GB0315889D0 (en) * | 2003-07-08 | 2003-08-13 | Aventis Pharma Ltd | Stable pharmaceutical products |
| US20060009435A1 (en) * | 2004-06-23 | 2006-01-12 | Joseph Kaspi | Synthesis and powder preparation of fluticasone propionate |
| AU2006297037A1 (en) * | 2005-09-28 | 2007-04-05 | Merck Frosst Canada Ltd | Aerosol powder formulation comprising sieved lactose |
| GB0801876D0 (en) * | 2008-02-01 | 2008-03-12 | Vectura Group Plc | Suspension formulations |
| TR200909788A2 (tr) * | 2009-12-25 | 2011-07-21 | Bi̇lgi̇ç Mahmut | Tiotropyum içeren inhalasyona uygun kuru toz formülasyonu |
| US8834931B2 (en) | 2009-12-25 | 2014-09-16 | Mahmut Bilgic | Dry powder formulation containing tiotropium for inhalation |
| PE20151332A1 (es) | 2013-02-19 | 2015-09-20 | Pfizer | Compuestos de azabencimidazol |
| KR20150076005A (ko) | 2013-12-26 | 2015-07-06 | 삼성디스플레이 주식회사 | 액정 표시 장치 |
| JP6713982B2 (ja) | 2014-07-24 | 2020-06-24 | ファイザー・インク | ピラゾロピリミジン化合物 |
| KR102061952B1 (ko) | 2014-08-06 | 2020-01-02 | 화이자 인코포레이티드 | 이미다조피리다진 화합물 |
| PL3494962T3 (pl) * | 2014-09-15 | 2021-12-06 | Verona Pharma Plc | Ciekła wziewna kompozycja farmaceutyczna zawierająca RPL554 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6004974A (en) * | 1995-06-06 | 1999-12-21 | Pfizer Inc | Tricyclic 5,6-dihydro-9h-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridines |
| US5985309A (en) * | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| DE19835346A1 (de) * | 1998-08-05 | 2000-02-10 | Boehringer Ingelheim Pharma | Zweiteilige Kapsel zur Aufnahme von pharmazeutischen Zubereitungen für Pulverinhalatoren |
-
2001
- 2001-09-12 GB GBGB0122031.8A patent/GB0122031D0/en not_active Ceased
-
2002
- 2002-09-02 JP JP2003526404A patent/JP2005505560A/ja not_active Withdrawn
- 2002-09-02 SK SK127-2004A patent/SK1272004A3/sk not_active Application Discontinuation
- 2002-09-02 HU HU0401890A patent/HUP0401890A3/hu unknown
- 2002-09-02 CZ CZ2004310A patent/CZ2004310A3/cs unknown
- 2002-09-02 CN CNA028178874A patent/CN1553801A/zh active Pending
- 2002-09-02 EP EP02767763A patent/EP1427414A1/en not_active Withdrawn
- 2002-09-02 OA OA1200400071A patent/OA12660A/en unknown
- 2002-09-02 IL IL16038002A patent/IL160380A0/xx unknown
- 2002-09-02 EE EEP200400078A patent/EE200400078A/xx unknown
- 2002-09-02 NZ NZ530929A patent/NZ530929A/en unknown
- 2002-09-02 MX MXPA04002354A patent/MXPA04002354A/es not_active Application Discontinuation
- 2002-09-02 EA EA200400301A patent/EA006742B1/ru not_active IP Right Cessation
- 2002-09-02 WO PCT/IB2002/003599 patent/WO2003022275A1/en not_active Application Discontinuation
- 2002-09-02 KR KR10-2004-7003619A patent/KR20040036940A/ko active IP Right Grant
- 2002-09-02 WO PCT/IB2002/003598 patent/WO2003022279A1/en not_active Application Discontinuation
- 2002-09-02 PL PL02368736A patent/PL368736A1/xx not_active Application Discontinuation
- 2002-09-02 BR BR0212449-1A patent/BR0212449A/pt not_active IP Right Cessation
- 2002-09-02 CA CA002457717A patent/CA2457717A1/en not_active Abandoned
- 2002-09-05 US US10/236,228 patent/US20030064034A1/en not_active Abandoned
- 2002-09-05 US US10/236,551 patent/US20030064031A1/en active Pending
- 2002-09-10 PE PE2002000894A patent/PE20030443A1/es not_active Application Discontinuation
- 2002-09-10 PE PE2002000893A patent/PE20030509A1/es not_active Application Discontinuation
- 2002-09-10 AR ARP020103426A patent/AR036473A1/es unknown
- 2002-09-10 AR ARP020103427A patent/AR036474A1/es unknown
- 2002-09-11 HN HN2002000253A patent/HN2002000253A/es unknown
- 2002-09-11 TW TW094130352A patent/TW200602054A/zh unknown
- 2002-09-12 AP APAP/P/2002/002623A patent/AP2002002623A0/en unknown
- 2002-09-12 SV SV2002001227A patent/SV2004001227A/es not_active Application Discontinuation
- 2002-09-12 PA PA20028554701A patent/PA8554701A1/es unknown
- 2002-09-12 SV SV2002001226A patent/SV2004001226A/es not_active Application Discontinuation
- 2002-09-12 PA PA20028554601A patent/PA8554601A1/es unknown
- 2002-09-12 AP APAP/P/2002/002624A patent/AP2002002624A0/en unknown
- 2002-10-11 HN HN2002000254A patent/HN2002000254A/es unknown
-
2004
- 2004-02-06 ZA ZA200401002A patent/ZA200401002B/en unknown
- 2004-02-09 BG BG108569A patent/BG108569A/bg unknown
- 2004-02-13 IS IS7151A patent/IS7151A/is unknown
- 2004-02-19 HR HR20040162A patent/HRP20040162A2/xx not_active Application Discontinuation
- 2004-02-26 MA MA27550A patent/MA27062A1/fr unknown
- 2004-03-10 NO NO20041011A patent/NO20041011L/no not_active Application Discontinuation
- 2004-03-10 TN TNP2004000040A patent/TNSN04040A1/fr unknown
- 2004-03-12 EC EC2004005018A patent/ECSP045018A/es unknown
-
2005
- 2005-06-13 US US11/152,741 patent/US20050232871A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20050232871A1 (en) | Use of compounds in a dry powder inhaler | |
| KR101742140B1 (ko) | 무스카린성 수용체 길항제 및 베타-２ 아드레날린 수용체 효능제의 조합물 | |
| US10583082B2 (en) | Composition comprising at least two dry powders obtained by spray drying to increase the stability of the formulation | |
| KR20100063116A (ko) | 치료제들의 복합제 | |
| AU2021200503B2 (en) | Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation | |
| KR20140041699A (ko) | 우메클리디늄 및 코르티코스테로이드를 포함하는 조합물 | |
| JP2011500731A (ja) | 併用療法 | |
| AU2021200396B2 (en) | Pharmaceutical composition containing budesonide and formoterol | |
| AU2002330687A1 (en) | Inhalation compositions comprising tricyclis 5,6-dihydro-9H-pyrazolo (3,4-c)-1,2,4-triazolo (4,3-alpha) pyridines | |
| BR112017007142B1 (pt) | Composição farmacêutica para uso inalatório na forma de pó compreendendo budesonida e formoterol e kit compreendendo a referida composição |